BPB 101
Alternative Names: BPB-101Latest Information Update: 25 May 2023
At a glance
- Originator Betta Pharmaceuticals Co Ltd
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants; Transforming growth factor beta1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 25 May 2023 NMPA approves clinical trial application for BPB 101 in Solid tumours in China (Betta Pharmaceuticals pipeline, May 2023)
- 16 May 2023 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater, Monotherapy) in China (IV) (NCT05869240)
- 10 May 2023 Betta Pharmaceuticals plans a phase I/II trial for Solid tumours (Late-stage disease, Metastatic disease) by May 2023 (IV) (NCT05869240)